In today’s clinical oncology practice, the saying “no two cancers are alike” is more relevant than ever. I recently treated two patients with very similar advanced non-small cell lung cancer (NSCLC) who were both critically ill. However, molecular profiling revealed distinct genetic drivers for each case, leading to very different, highly customized treatment plans. Patient
EGFR vs. ALK: How molecular profiling defines lung cancer treatment originally appeared in KevinMD.com.
Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.